Elastomeric infusion pumps, also known as disposable balloon pumps, are used to administer intravenous (IV) drugs such as local anesthetics, antibiotics, and anti-neoplastic. These non-electronic, non-gravity driven devices are used in single infusions. Elastomeric infusion pumps contain a stretchable balloon reservoir that is filled with a drug and pressure from the elastic walls drives fluid delivery with relatively consistent pressure until it reaches near the end of the infusion.
Global elastomeric infusion pumps market is estimated to be valued at US$ 1,067.8 million in 2022 and is expected to exhibit a CAGR of 9.2% during the forecast period (2022-2030).
Figure 1. Global Elastomeric Infusion Pumps Market Share (%), by Treatment, 2022
Post-operative pain in surgeries such as total knee replacement and total hip replacement is usually treated by infusion of analgesics through disposable infusion pumps. Therefore, increasing number of orthopedic procedures and surgeries is expected to boost growth of the global elastomeric infusion pumps market over the forecast period.
For instance, according to a 2018 report by American Academy of Orthopedic Surgeons, over 1 million patients and over 1.4 million hip and knee arthroplasty procedures were entered into the American Joint Replacement Registry.
|Base Year:||2021||Market Size in 2022:||US$ 1,067.8 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||9.2%||2030 Value Projection:||US$ 2,163.8 Mn|
B. Braun Melsungen AG, Fresenius Kabi, Leventon, S.A.U, Ambu A/S, Baxter International Inc., Halyard Health, and Nipro Corporation
|Restraints & Challenges:||
Figure 2. Global Elastomeric Infusion Pumps Market Share (%), by Region, 2022
The increasing incidence of chronic blood diseases such as blood cancer is expected to drive growth of the global elastomeric infusion pumps market over the forecast period.
The increasing incidence of chronic blood diseases such as blood cancers which include leukemia, lymphoma, and myeloma or blood disorders such as anemia or bleeding disorders such as blood clots and hemophilia is expected to drive growth of the global elastomeric infusion pumps market over the forecast period.
For instance, According to the Centers for Disease Control and Prevention (CDC) in 2019, the Sickle Cell Disease (SCD) affects around 100,000 Americans each year. Moreover, according to Leukemia & Lymphoma Society, it was estimated that around 172,910 people in the U.S. were expected to be diagnosed with the leukemia, lymphoma or myeloma in 2017.
Global Elastomeric Infusion Pumps Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.
COVID-19 has affected the economy in three main ways: by directly affecting production and demand of drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, UAE, Egypt, and others, faced problems with regard to the transportation of drugs and vaccines from one place to another. Elastomeric infusion pumps market faced negative impact due COVID-19 as there was lack of transportation facility of raw material used to manufacture infusion pumps.
Global Elastomeric Infusion Pumps Market: Key Developments
On June 22, 2022, Delta Med, an Italy-based company involved in the vascular access devices market, announced that they acquired Adria Med, a company manufacturing elastomeric infusion pumps, to strengthen their positioning in the infusion systems market
Global Elastomeric Infusion Pumps Market: Restraint
The costs of elastomeric infusion pumps keep fluctuating depending on the type of the pumps. For instance, the cost of pumps administering antibiotics is significantly low, whereas the cost of pumps administering pain management drugs is relatively high. Such scenario is expected to hinder growth of the global elastomeric infusion pumps market over the forecast period.
Moreover, stringent regulations regarding the use of plastics in elastomeric infusion pumps is also expected to hamper the market growth. For instance, the European Commission and the U.S. Food and Drug Administration (FDA) published safety assessments of medical devices containing Di (2-ethylhexyl) phthalate (DEHP) and plasticized polyvinylchloride (PVC) in parts of elastomeric infusion pumps. Therefore, manufacturers need to focus on proper safety labeling of products to avoid severe side effects, especially in neonatal patient population.
Major players operating in the global elastomeric infusion pumps market include B. Braun Melsungen AG, Fresenius Kabi, Leventon, S.A.U, Ambu A/S, Baxter International Inc., Halyard Health, and Nipro Corporation.
Elastomeric infusion pumps are non-electronic medication pumps also called as balloon pumps which are used for infusion of analgesics, chemotherapy drugs, local anesthetics, antibiotics and other type of medications. Elastomeric infusion pumps are single use medical devices used for drug infusion. The process of infusion is carried out with the help of consistent pressure created in the elastomeric layer present in the pump which is controlled with the help of flow restrictors located in the elastomeric reservoir.
Increase in the prevalence of chronic diseases like cancer is expected to propel growth of market. For instance, according to factsheet published by World Health Organization (WHO) on 3 February, 2022, nearly 10 million deaths, or nearly one in six deaths were caused by cancer in 2020, making it the leading cause of death globally. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. In addition, according to WHO, each year, approximately 400,000 children develop cancer. Thus due to prevalence of cancer the global elastomeric infusion pumps market is expected grow over the forecast period.
Moreover, elastomeric infusion pumps are cheaper and have fewer adverse effects compared to electronic pumps, which increases their adoption in ambulatory chemotherapy infusion centers. Moreover, as elastomeric infusion pumps do not require electricity to operate, the risk for free flow of medication to patients is eliminated. Such advantages of elastomeric infusion pumps over their electric counterparts is also expected to boost growth of market.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.View All Our Clients